Brain Cancer Market Forecasts to 2034 - Global Analysis By Tumor Type, Treatment Type, Diagnosis, Treatment Setting, Patient Age Group and By Geography

According to Stratistics MRC, the Global Brain Cancer Market is accounted for $4.2 billion in 2026 and is expected to reach $8.1 billion by 2034 growing at a CAGR of 8.6% during the forecast period. The Brain Cancer Market focuses on diagnostic technologies, surgical interventions, radiation therapy, chemotherapy, targeted therapies, immunotherapy, and tumor treating fields for managing malignant and selected other brain tumors. Increasing demand for advanced neuro-oncology treatments, improvements in early diagnosis, and growing investment in cancer research are supporting market expansion. Advancements in molecular profiling, precision oncology, stereotactic radiosurgery, and tumor treating fields are improving treatment approaches. Expanding healthcare infrastructure, increasing access to specialized cancer centers, and continued development of innovative therapeutics are further encouraging market growth worldwide.

Market Dynamics:

Driver:

Increasing demand for advanced brain tumor diagnosis and treatment

The increasing demand for advanced brain tumor diagnosis and treatment is a major driver of the brain cancer market. Improvements in magnetic resonance imaging, molecular testing, and neurosurgical techniques are supporting more accurate tumor classification and individualized treatment planning. Growing awareness of neurological symptoms and expanding access to specialized oncology services are encouraging earlier clinical evaluation. Increasing adoption of precision medicine, advanced radiation technologies, and multidisciplinary treatment approaches is strengthening demand for specialized care. Continued investment in neuro-oncology research and clinical infrastructure is further supporting market development.

Restraint:

High treatment costs and limited effectiveness of existing therapies

High treatment costs and the limited effectiveness of available treatments for aggressive brain tumors are significant restraints on market expansion. Complex neurosurgical procedures, advanced radiation therapy, molecular diagnostics, and innovative oncology medications can create substantial financial burdens. The blood-brain barrier also restricts the delivery of many systemic treatments to intracranial tumors. Additionally, glioblastoma and certain other malignant brain tumors frequently recur despite intensive treatment. Limited specialist availability, treatment-related neurological complications, and unequal access to advanced cancer centers further complicate disease management, particularly in developing healthcare markets.

Opportunity:

Development of precision oncology and innovative brain tumor therapies

Advancements in precision oncology, targeted therapies, and emerging treatment technologies are creating significant opportunities for market participants. Molecular profiling enables the identification of actionable alterations, including selected IDH mutations, BRAF alterations, and other tumor-specific biomarkers. Pharmaceutical companies are investigating novel immunotherapies, antibody-based treatments, and therapeutic approaches designed to improve drug delivery to the central nervous system. Developments in tumor treating fields, image-guided radiation therapy, and artificial intelligence-assisted diagnostics are also encouraging innovation. Expanding clinical trials and international research collaborations may further accelerate treatment development.

Threat:

Clinical trial challenges and stringent regulatory requirements

Stringent regulatory requirements and challenges associated with brain cancer clinical trials present significant market threats. Developers must demonstrate meaningful improvements in survival, disease control, or patient outcomes while maintaining acceptable safety profiles. Small patient populations within specific molecular subtypes can complicate clinical trial recruitment and statistical evaluation. Tumor heterogeneity, treatment resistance, and difficulty achieving adequate drug penetration into the brain create additional development risks. Furthermore, reimbursement restrictions, competition from established treatment approaches, and potential adverse effects may influence commercial adoption of innovative therapies.

Covid-19 Impact:

The COVID-19 pandemic affected the brain cancer market through disruptions in diagnostic imaging, elective neurosurgical procedures, radiation therapy scheduling, and clinical research activities. Healthcare resource constraints and travel restrictions complicated access to specialized neuro-oncology services for some patients. Delays in diagnosis and treatment planning created additional challenges for individuals with rapidly progressing tumors. However, telemedicine consultations, remote multidisciplinary assessments, and digital patient monitoring gained importance during the pandemic. Subsequent recovery in oncology services, renewed clinical trial activity, and continued investment in advanced cancer treatments supported market stabilization and development.

The glioblastoma segment is expected to be the largest during the forecast period

The glioblastoma segment is expected to account for the largest market share during the forecast period due to its aggressive clinical behavior, intensive treatment requirements, and substantial need for specialized oncology care. Glioblastoma is among the most common malignant primary brain tumors in adults and frequently requires a combination of surgery, radiation therapy, and chemotherapy. Its high recurrence rate creates continued demand for additional treatment options and clinical monitoring. Increasing research into tumor treating fields, targeted therapies, and novel drug delivery systems is supporting segment development. Continued clinical trial investment further strengthens its market significance.

The immunotherapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the immunotherapy segment is predicted to witness the highest growth rate due to increasing research into immune-based approaches for treating malignant brain tumors. Investigational strategies include therapeutic vaccines, engineered cellular therapies, immune checkpoint combinations, and oncolytic viruses. These approaches aim to overcome tumor-associated immune suppression and improve antitumor responses. Advances in molecular characterization and biomarker research are supporting more selective clinical trial designs. However, the clinical effectiveness of many immunotherapies in brain cancer remains under investigation, and future commercial growth will depend on successful trials and regulatory approvals.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share, supported by advanced oncology infrastructure, substantial healthcare expenditure, and strong clinical research capabilities. The United States represents a major market due to established neuro-oncology centers, extensive access to diagnostic imaging, and the presence of leading pharmaceutical and medical technology companies. Increasing adoption of molecular testing, precision oncology treatments, and advanced radiation technologies is supporting market development. Continued investment in clinical trials, specialized neurosurgical services, and innovative treatment platforms further strengthens regional performance.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR due to expanding cancer care infrastructure, improving diagnostic capabilities, and increasing investment in specialized oncology services. China, Japan, India, South Korea, and Australia represent important markets for brain tumor diagnosis and treatment. Growing availability of MRI systems, molecular testing, and advanced radiation therapy equipment is supporting treatment accessibility. Rising healthcare expenditure, increasing clinical research activity, and expanding specialist cancer centers are further encouraging regional development. Government initiatives to strengthen cancer care services may also support long-term market growth.

Key players in the market

Some of the key players in the Brain Cancer Market include F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb, Novartis AG, Pfizer Inc., AstraZeneca plc, Eli Lilly and Company, Bayer AG, Amgen Inc., Jazz Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Novocure Limited, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Medtronic plc, Siemens Healthineers AG, and GE HealthCare Technologies Inc.

Key Developments:

In September 2025, Jazz Pharmaceuticals announced that Modeyso (dordaviprone) had been included in the National Comprehensive Cancer Network clinical practice guidelines as a category 2A treatment option for recurrent or progressive H3 K27M-mutant diffuse high-grade glioma. The inclusion followed its FDA accelerated approval and represented an important development in clinical recognition of molecularly targeted brain tumor treatments.

In August 2025, Jazz Pharmaceuticals received U.S. FDA accelerated approval for Modeyso (dordaviprone) to treat adults and children aged one year and older with progressive H3 K27M-mutant diffuse midline glioma following prior therapy. The approval was supported by an integrated analysis of five clinical studies and introduced the first FDA-approved systemic treatment for this specific aggressive brain tumor subtype.

In April 2025, Jazz Pharmaceuticals completed its acquisition of Chimerix for approximately $944.2 million in cash, strengthening its neuro-oncology portfolio through the addition of dordaviprone. The acquisition provided Jazz with a late-stage therapeutic candidate for H3 K27M-mutant diffuse glioma, supporting its expansion into specialized brain cancer treatments and establishing a foundation for subsequent regulatory and commercialization activities.

Tumor Types Covered:

• Glioblastoma
• Astrocytoma
• Oligodendroglioma
• Ependymoma
• Medulloblastoma
• Meningioma
• Other Tumor Types

Treatment Types Covered:

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Tumor Treating Fields

Diagnostics Covered:

• MRI
• CT Scan
• Biopsy & Histopathology
• Molecular & Genetic Testing
• Other Diagnostics

Treatment Settings Covered:

• Hospitals
• Specialty Cancer Centers
• Ambulatory Surgical Centers

Patient Age Groups Covered:

• Pediatric
• Adult
• Geriatric

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances